denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
This scientific session will highlight the mechanisms that regulate thrombus initiation and propagation, review the role of neutrophils in thrombosis, discuss the crosstalk between NETs and intrinsic coagulation pathway and describe new methods for both imaging and targeting thrombosis.
Dr. Martinod will discuss the pathological role of NETs in various human diseases. She will emphasize the importance of citrullinated histones, generated during NET formation by the peptidyl arginine deaminase 4 (PAD4), as useful biomarkers of ongoing NET formation. She will summarize studies in animal models showing protective effects of PAD4-deficiency in MPN-driven thrombosis and cardiac fibrosis. Dr. Martinod’s presentation will provide insight into potential therapeutic approaches to inhibiting NETs.
Dr. Evi Stavrou will present novel insights into the role of neutrophils in in vivo models of thrombosis. While an integral component of the innate immune response, recent evidence supports that unrestricted recruitment and function of activated neutrophils can prolong inflammation and contribute to the development of pathologic conditions including vascular thrombosis. Dr. Stavrou will discuss how disease-specific factors, animal model selection, and specific vascular beds impact neutrophil activities, the signaling pathways they intersect, and how targeting neutrophil components can be exploited for prognostic and therapeutic development against thrombosis.
Dr. Ioannis Mitroulis will present recent evidence derived from animal models and clinical observations, demonstrating the critical involvement of cells of the myeloid lineage in venous thrombosis. He will provide an overview on immunothrombosis as a mechanism that links the activation of neutrophils and monocytes with thrombotic disorders. His presentation will focus on thrombotic complications associated with hematopoietic malignancies and solid tumors, as well as with infectious and inflammatory disorders including COVID-19. Dr. Mitroulis will also discuss how the inflammatory environment in such disorders reprograms neutrophils and monocytes towards a pro-thrombotic phenotype.
Dr. Martinod will discuss the pathological role of NETs in various human diseases. She will emphasize the importance of citrullinated histones, generated during NET formation by the peptidyl arginine deaminase 4 (PAD4), as useful biomarkers of ongoing NET formation. She will summarize studies in animal models showing protective effects of PAD4-deficiency in MPN-driven thrombosis and cardiac fibrosis. Dr. Martinod’s presentation will provide insight into potential therapeutic approaches to inhibiting NETs.
Dr. Evi Stavrou will present novel insights into the role of neutrophils in in vivo models of thrombosis. While an integral component of the innate immune response, recent evidence supports that unrestricted recruitment and function of activated neutrophils can prolong inflammation and contribute to the development of pathologic conditions including vascular thrombosis. Dr. Stavrou will discuss how disease-specific factors, animal model selection, and specific vascular beds impact neutrophil activities, the signaling pathways they intersect, and how targeting neutrophil components can be exploited for prognostic and therapeutic development against thrombosis.
Dr. Ioannis Mitroulis will present recent evidence derived from animal models and clinical observations, demonstrating the critical involvement of cells of the myeloid lineage in venous thrombosis. He will provide an overview on immunothrombosis as a mechanism that links the activation of neutrophils and monocytes with thrombotic disorders. His presentation will focus on thrombotic complications associated with hematopoietic malignancies and solid tumors, as well as with infectious and inflammatory disorders including COVID-19. Dr. Mitroulis will also discuss how the inflammatory environment in such disorders reprograms neutrophils and monocytes towards a pro-thrombotic phenotype.